Novavax Inc. / SK Bioscience Co., Ltd.

COVID-19 prevention (NVX-CoV2373 vaccine commercialization in South Korea)

27.8M US cases/yr · $50.0B Global COVID-19 vaccine procurement commitments 2021 (USD MM) · 40000000 South Korea NVX-CoV2373 dose commitment

Disease Overview

COVID-19 (SARS-CoV-2) emerged in late 2019 and triggered the largest global vaccine development effort in history. By February 2021, when this Novavax/SK Bioscience deal was announced, the United States had recorded approximately 27.8 million confirmed cases and 489,000 deaths (CDC), and South Korea had 84,946 confirmed cases. The 2021 global vaccine market for COVID-19 alone exceeded $50 billion in disclosed government procurement commitments, with Pfizer/BioNTech (Comirnaty), Moderna (Spikevax), AstraZeneca/Oxford (Vaxzevria), Johnson & Johnson (Janssen) and CoronaVac (Sinovac) leading the early supply. South Korea's Korea Disease Control and Prevention Agency (KDCA) targeted ~70% population coverage and pre-purchased Pfizer, Moderna, AstraZeneca, Janssen and Novavax doses. Novavax's NVX-CoV2373 was a recombinant spike protein nanoparticle vaccine adjuvanted with proprietary saponin-based Matrix-M, with Phase 3 PREVENT-19 (US/Mexico) and a UK Phase 3 trial reading out in early 2021. The vaccine was the only major US-developed candidate using a recombinant protein subunit approach versus mRNA (Pfizer, Moderna), adenoviral vector (AstraZeneca, J&J) or whole inactivated virus (Sinovac, Sinopharm). South Korea's KDCA committed to 40 million doses (20 million two-dose regimens) of NVX-CoV2373 produced domestically by SK Bioscience for the Korean population.

Competitive Landscape

By Q1 2021, the COVID-19 vaccine landscape was dominated by mRNA platforms — Pfizer/BioNTech Comirnaty (BNT162b2, EUA Dec 2020) and Moderna Spikevax (mRNA-1273, EUA Dec 2020) — alongside AstraZeneca/Oxford Vaxzevria (ChAdOx1, viral vector), Johnson & Johnson Janssen (Ad26.COV2.S, viral vector, EUA Feb 2021), Sinovac CoronaVac (whole inactivated), Sinopharm BBIBP-CorV (whole inactivated), and Bharat Biotech Covaxin. Recombinant protein subunit competitors to NVX-CoV2373 included Sanofi/GSK SP/MF59 (Phase 1 readout disappointing Dec 2020, reformulated and relaunched), Clover Biopharmaceuticals SCB-2019 (S-trimer, CEPI-funded), Medigen MVC-COV1901 (Taiwan), and SKYCovione (SK Bioscience's own internally developed recombinant spike nanoparticle co-developed with University of Washington/IPD). South Korea's domestic vaccine industry included SK Bioscience (KOSPI:302440), Celltrion (CT-P59 regdanvimab antibody, anti-COVID monoclonal approved by MFDS Feb 2021) and GC Pharma (plasma-derived therapeutics). SK Bioscience operated as the spinoff of SK Chemicals' vaccine division and provided contract manufacturing for AstraZeneca Vaxzevria production at its Andong L-House facility from late 2020. The expanded Novavax-SK Bioscience agreement followed an Aug 2020 initial CDMO agreement and reflected SK Bioscience's strategy to combine internal R&D with technology in-licensing and CDMO services.